Pounding the Compounders: FDA’s “No Compound” Lists
Novo Nordisk recently made headlines petitioning FDA to stop the compounding of its blockbuster GLP-1 products so it can sell its patented semaglutide drugs exclusively.
Competition Law Developments in Germany: Three Things We Are Watching
As counsel to global companies, we often guide clients through not just U.S. antitrust issues, but also through a global antitrust landscape. Whether it is a merger or a business practice, it is crucial to understand how all the global pieces fit together.
HSR Overhaul Goes Into Effect
In a significant milestone for antitrust merger practice and after considerable uncertainty, new HSR rules came into effect today, February 10, 2025. Companies engaged in M&A now face higher burdens in preparing filings, leading to increased cost and potential delays, particularly as dealmakers and the agencies adapt to the “new normal.”
Pounding the Compounders: FDA’s “No Compound” Lists
Novo Nordisk recently made headlines petitioning FDA to stop the compounding of its blockbuster GLP-1 products so it can sell its patented semaglutide drugs exclusively.
Competition Law Developments in Germany: Three Things We Are Watching
As counsel to global companies, we often guide clients through not just U.S. antitrust issues, but also through a global antitrust landscape. Whether it is a merger or a business practice, it is crucial to understand how all the global pieces fit together.
HSR Overhaul Goes Into Effect
In a significant milestone for antitrust merger practice and after considerable uncertainty, new HSR rules came into effect today, February 10, 2025. Companies engaged in M&A now face higher burdens in preparing filings, leading to increased cost and potential delays, particularly as dealmakers and the agencies adapt to the “new normal.”
Pounding the Compounders: FDA’s “No Compound” Lists
Novo Nordisk recently made headlines petitioning FDA to stop the compounding of its blockbuster GLP-1 products so it can sell its patented semaglutide drugs exclusively.
Insights
